Brivaracetam in the treatment of epilepsy: a review of clinical trial data.

51 In another Phase IIb, double-blind, randomized, placebo-controlled, parallel-group, dose-ranging study (N01114), the primary efficacy analysis did not reach statistical significance, however statistically significant differences were observed as compared with placebo on several secondary efficacy outcomes with BRV at a 50 mg daily dose. 52 Details of BRV efficacy results from these clinical trials are summarized in Table 2 .

also in 111,027 other papers